Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYVIBE-008 in first-line extensive-stage small cell lung cancer
2021-005034-42Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vibostolimab + pembrolizumab, atezolizumab and etoposide in small cell lung cancer (SCLC) (2 arms), sponsored by Merck & Co. Primary endpoint: Overall Survival. Started Dec 2021; status: active.
02
Drugs
vibostolimab + pembrolizumabatezolizumabetoposide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2021-005034-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005034-42.